Department of Digestive Surgery and Transplantation, CHU Lille, University Lille, Lille, France.
Department of Digestive Pathology, Surgery Unit, CHU Clermont Ferrand Hôtel Dieu NHE, Clermont Ferrand, France.
Ann Surg. 2021 Nov 1;274(5):874-880. doi: 10.1097/SLA.0000000000005121.
To compare 2 techniques of remnant liver hypertrophy in candidates for extended hepatectomy: radiological simultaneous portal vein embolization and hepatic vein embolization (HVE); namely LVD, and ALPPS.
Recent advances in chemotherapy and surgical techniques have widened indications for extended hepatectomy, before which remnant liver augmentation is mandatory. ALPPS and LVD typically show higher hypertrophy rates than portal vein embolization, but their respective places in patient management remain unclear.
All consecutive ALPPS and LVD procedures performed in 8 French centers between 2011 and 2020 were included. The main endpoint was the successful resection rate (resection rate without 90-day mortality) analyzed according to an intention-to-treat principle. Secondary endpoints were hypertrophy rates, intra and postoperative outcomes.
Among 209 patients, 124 had LVD 37 [13,1015] days before surgery, whereas 85 underwent ALPPS with an inter-stages period of 10 [6, 69] days. ALPPS was mostly-performed for colorectal liver metastases (CRLM), LVD for CRLM and perihilar cholangiocarcinoma. Hypertrophy was faster for ALPPS. Successful resection rates were 72.6% for LVD ± rescue ALPPS (n = 6) versus 90.6% for ALPPS (P < 0.001). Operative duration, blood losses and length-of-stay were lower for LVD, whereas 90-day major complications and mortality were comparable. Results were globally unchanged for CRLM patients, or after excluding the early 2 years of experience (learning-curve effect).
This study is the first 1 comparing LVD versus ALPPS in the largest cohort so far. Despite its retrospective design, it yields original results that may serve as the basis for a prospective study.
比较两种用于扩大肝切除术候选者残肝增生的技术:放射学门静脉栓塞联合肝静脉栓塞(HVE),即 LVD 和 ALPPS。
化疗和外科技术的最新进展拓宽了扩大肝切除术的适应证,在此之前必须进行残肝增生。ALPPS 和 LVD 通常比门静脉栓塞显示出更高的增生率,但它们在患者管理中的各自位置仍不清楚。
纳入 2011 年至 2020 年在 8 个法国中心进行的所有连续 ALPPS 和 LVD 手术。主要终点是根据意向治疗原则分析的成功切除率(无 90 天死亡率的切除率)。次要终点是增生率、围手术期结果。
在 209 名患者中,124 名患者在手术前 37 [13,1015] 天接受了 LVD,而 85 名患者接受了 ALPPS,其间隔期为 10 [6,69] 天。ALPPS 主要用于结直肠癌肝转移(CRLM),LVD 用于 CRLM 和肝门部胆管癌。ALPPS 的增生速度更快。LVD ± 挽救性 ALPPS(n = 6)的成功切除率为 72.6%,而 ALPPS 的成功切除率为 90.6%(P < 0.001)。LVD 的手术时间、失血量和住院时间较低,而 90 天主要并发症和死亡率相当。对于 CRLM 患者,或在排除早期 2 年的经验(学习曲线效应)后,结果基本不变。
这是迄今为止首次将 LVD 与 ALPPS 进行比较的研究。尽管其设计为回顾性,但它产生了原始结果,可为前瞻性研究提供依据。